Small Cap Feast
Small Cap Feast – 26 June 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
The pantry is bare!
Redcentric 127p £189m (RCN.L)
The UK IT managed services provider has issued a trading update. The Board has been encouraged by the Company’s trading performance in the year to date, with recurring revenue orders received in Q1 FY21 expected to be marginally ahead of Q1 FY20 and significantly ahead of the Board’s expectations at the time of the last trading update and COVID-19 update released on 3rd April 2020. In addition, customer installations in the quarter are expected to be significantly higher than the equivalent period last year and ahead of expectations at the time of the last trading update.
Sativa Group 3.125p £17.8m (AQSE:SATI)
The CBD wellness and medicinal cannabis Group, is working on its Novel Food application in partnership with Stillcanna Inc, and is committed to meeting the requirements of the Food Standards Agency (“FSA”) concerning the safe use of CBD products and the timetable for Novel Food authorisation. The FSA is giving the CBD industry a deadline of the 31(st) March 2021 to submit valid novel food authorisation applications. After 31st March next year, only products which have submitted a valid application will be allowed to remain on the market. The authorisation process ensures novel foods meet legal standards, including on safety and content.
With the novel food’s authorisation, it will mean that there is a two-step process in applications. Step one, the manufacturers of the CBD ingredient, (extract or isolate) of which genotoxicity and toxicology testing are part of that process, and step two, the manufacturer of the end consumer product who will need to conduct stability testing and apply for novel foods authorisation. Henry Lees-Buckley, Chief Executive Office of Sativa, said: “We welcome and embrace the clarity of the regulatory framework as an important step to leading the development of a safe and legal market in the UK. We are taking seriously the guidance from the FSA to reassure our customers and distribution partners that Sativa and StillCanna are at the forefront of building a sustainable CBD wellness industry. We have invested in our infrastructure to ensure that we are fully compliant with industry regulation for each step of the manufacturing process of our CBD products. By owing each step of that process we can ensure that compliance is maintained throughout”
Windar Photonics 20p £8m (WPHO.L)
The technology group that has developed a cost efficient and innovative LiDAR wind sensor for use on electricity generating wind turbines, announces an unaudited trading update for the year ended 31 December 2019 and also for 2020 year to date.
2019 trading update—· Revenue EUR1.2 million (2018: EUR3.5 million) – · Operating costs (ex. depreciation, amortisation and warrant costs) of EUR2.5 million (2018: EUR2.2 million)
- EBITDA loss of EUR1.9 million (2018: loss EUR0.4 million) -· Net cash of EUR1.4 million including restricted cash holdings* of EUR0.4 million (2018: EUR2.2 million and EUR0.5 million, respectively) -· Trade receivables at 31 December 2019 of EUR0.5 million (2018: EUR0.6 million) – · Order backlog at the end of 2019 for deliveries in 2020 totalled EUR0.1 million (2018: EUR1.0 million)
Given the Company’s concentration of contracts for projects in China and with Chinese clients generally, there has been a slowdown in delivery of LiDAR and other equipment compared with internal budgets, principally due to the global slowdown resulting from the COVID-19 pandemic. Despite this, the Company has obtained orders in 2020 to date for more than EUR1.7 million for delivery in 2020. The current order backlog and sales pipeline for the rest of 2020 and 2021 are stronger that as at 31 December 2019. In addition, 2020 is seeing, for the first time in the Company’s history, sustained progress from the OEM market. However, given the inherent uncertainties surrounding COVID-19, the Board continues to believe it is inappropriate to provide forward looking guidance to investors and analysts at the current time.
Warpaint London 69p £53m (W7L.L)
“Whilst trading conditions remain challenging as a result of the COVID-19 pandemic, sales in the first half of 2020 have been at a higher level than anticipated, albeit significantly below the first half of 2019. There has been an improvement in margin, no erosion of cash and a positive EBITDA for the first 6 months of the current year.
“The Group has a sound financial footing and we are actively implementing our strategy for growth. We look forward to the remainder of the year with cautious optimism.”
DP Poland 7.25p £18.4m (DPP.L)
AGM Update from DP Poland who through its wholly owned subsidiary DP Polska S.A., has the exclusive right to develop, operate and sub-franchise Domino’s Pizza stores in Poland. “Trading in 2020 has started broadly in line with management’s expectations. COVID-19 has had relatively little impact on our business in comparison to other businesses in our industry as we have been able to keep open all our stores and our 2 commissaries operating without interruption. As previously reported, from Saturday, 14 March 2020, the Polish government imposed ‘lock down’ restrictions across the country. As a result, like-for-like (“LFL”) System Sales and System Sales were down 14% and 10% respectively for the month of March. However, performance recovered in the following months, with LFL System Sales up by 3% and System Sales up by 6% in each of the months of April and May.
A positive impact of COVID-19 has been a reduction in our food and labour costs and in some of our rent costs. In addition, the recruitment market has improved for us, in terms of both availability of staff and labour costs. However we have also incurred some additional costs, principally in connection with safety and cleaning, across our operations to meet the requirements necessitated by COVID-19 regulations.
Inspiration Healthcare 69p £27.4m (IHC.L)
Appointment of Jonathan (Jon) Ballard as the Group’s Chief Financial Officer and Company Secretary with effect from 1 July 2020.
Jon joined Inspiration Healthcare in 2017 as Group Finance Controller and has worked alongside Mike Briant the retiring Chief Financial Officer for over 3 years. As has been previously announced, Mike Briant will retire from the Board at the end of June 2020 and will continue to work full time with the Group until the end of August and will then continue during a handover period part time until November 2020.
IQE 53p £423m (IQE.L)
The manufacturer of advanced semiconductor wafer products for the global semiconductor industry, today welcomes the UK Government’s approval of a major £43.74m project with South Wales’ compound semiconductor cluster. This comes as part of the first wave of funding through UK Research and Innovation’s flagship Strength in Places Fund (SIPF).
The project’s twelve partners include key Welsh Anchor Companies (IQE plc, Newport Wafer Fab (NWF) and SPTS), two universities (lead partner Cardiff University and Swansea University), CSC and several government organisations, including the Compound Semiconductor Applications Catapult.
The initiative is one of seven chosen to be supported by the UK Government as part of a broader £400m investment programme being announced today.
Kazera Global 0.63p £4.2m (KZG.L)
Kazera has increased its interest in African Tantalum (Pty) Limited (Aftan), who own the Tantalite Valley Mine (TVM) and the Tameka Shelf Company, to 100%, having acquired a further 25% interest.
Furthermore, the Company has announced the appointment of Mr Odilon Ilunga as an Executive Technical Director to the Board of the Company.
- Acquisition cost of £26,008 funded via low-cost issuance of 4,523,114 ordinary shares in the capital of the Company .o
The acquisition of the further 25% interest has been completed for the same number of shares relative to the 75% interest previously acquired by the Company, despite significant resource upgrades and progress being made to the Mine during this period and the share price being considerably lower than at the time of the original acquisition.
- Completes the Company’s long-term planned strategy of acquiring total control over TVM ahead of a significant period for the Mine where the Orange River Pipeline building project matures
- As a reminder to shareholders, cumulatively, Aftan de-risked JORC Compliant Mineral Resource Estimates of 622.2 kt of lithium and tantalite resources in it’s first exploration phase at the Mine since Kazera first invested, with the second phase ongoing
Marlowe 484.5p £223m (MRL.L)
Acquisition of Elogbooks, a leading provider of contractor management software and services, for an enterprise value of up to £14.05 million. The acquisition represents the next step in Marlowe’s strategy to deliver integrated technology and services to enhance the compliance, safety & upkeep of our clients’ premises
- Placing, by way of an accelerated bookbuild, expected to raise a minimum of £35 million at 478p to fund the acquisition and provide resources to accelerate the Group’s acquisition-led strategy amidst a favourable M&A climate
- Unaudited results for year ended 31 March 2020 (FY20):
o Adjusted EBITDA2 up 51% to £16.6 million
o Adjusted profit before tax2 up 52% to £13.6 million
Instem 440p £73.36m (INS.L)
Proposed £15.75m placing at 435p. The net proceeds of the Placing receivable by the Company will be used to accelerate the Group’s acquisition strategy with a number of potential compelling opportunities for bolt on acquisitions and more substantial targets having been identified.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.